ISR IsoRay

Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022

Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022

Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT

RICHLAND, Wash., Sept. 21, 2022 (GLOBE NEWSWIRE) --   (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2022 on Wednesday, September 28, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2022 after the close of the U.S. stock markets on September 28, 2022.

To listen to the conference call, please dial 888-506-0062. For callers outside the U.S., please dial 973-528-0011.

The conference call will be simultaneously webcast and can be accessed at . The webcast will be available until December 28, 2022 following the conference call.

About Isoray

Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting . Follow us on and .



Contact
Investor Relations: Mark Levin (501) 255-1910
Media and Public Relations: Sharon Schultz (302) 539-3747
EN
21/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IsoRay

 PRESS RELEASE

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Hea...

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) --  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT. 44th Annual J.P. Morgan Healthcare Conference – Company PresentationDate: Wednesday, January 14, 2026Ti...

 PRESS RELEASE

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Pr...

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) --  (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium () Congress 2026 taking place from January 8 to 10, 2026 in San Franc...

David Nierengarten ... (+9)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
 PRESS RELEASE

Perspective Therapeutics to Participate in Upcoming December Conferenc...

Perspective Therapeutics to Participate in Upcoming December Conferences SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 –  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside ChatDate: Tuesday, December 2, 2025Time: 1:00 - 1:25 p....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch